- Case Report
- Open Access
Ectopic corticotropin-releasing hormone (CRH) syndrome from metastatic small cell carcinoma: a case report and review of the literature
© Shahani et al; licensee BioMed Central Ltd. 2010
- Received: 11 August 2010
- Accepted: 31 August 2010
- Published: 31 August 2010
Cushing's Syndrome (CS) which is caused by isolated Corticotropin-releasing hormone (CRH) production, rather than adrenocorticotropin (ACTH) production, is extremely rare.
We describe the clinical presentation, course, laboratory values and pathologic findings of a patient with isolated ectopic CRH causing CS. We review the literature of the types of tumors associated with this unusual syndrome and the behavior of these tumors by endocrine testing.
A 56 year old woman presented with clinical and laboratory features consistent with ACTH-dependent CS. Pituitary imaging was normal and cortisol did not suppress with a high dose dexamethasone test, consistent with a diagnosis of ectopic ACTH. CT imaging did not reveal any discrete lung lesions but there were mediastinal and abdominal lymphadenopathy and multiple liver lesions suspicious for metastatic disease. Laboratory testing was positive for elevated serum carcinoembryonic antigen and the neuroendocrine marker chromogranin A. Serum markers of carcinoid, medullary thyroid carcinoma, and pheochromocytoma were in the normal range. Because the primary tumor could not be identified by imaging, biopsy of the presumed metastatic liver lesions was performed. Immunohistochemistry was consistent with a neuroendocrine tumor, specifically small cell carcinoma. Immunostaining for ACTH was negative but was strongly positive for CRH and laboratory testing revealed a plasma CRH of 10 pg/ml (normal 0 to 10 pg/ml) which should have been suppressed in the presence of high cortisol.
This case illustrates the importance of considering the ectopic production of CRH in the differential diagnosis for presentations of ACTH-dependent Cushing's Syndrome.
- Medullary Thyroid Carcinoma
- Corticotrophin Release Hormone
- Small Cell Lung Carcinoma
- Inferior Petrosal Sinus Sampling
- Ectopic ACTH Production
Cushing's syndrome (CS) comprises the clinical manifestations of exposure to elevated glucocorticoid hormones, either from exogenous sources or endogenous overproduction by the adrenal glands . CS from endogenous production is rare with an incidence of 0.7 to 2.5 per million per year depending on the geographic region and population studied . Although autonomous cortical adrenal adenomas or carcinomas are a cause of elevated cortisol, most cases (85 to 90%) are adrenocorticotropic hormone (ACTH) dependent and are caused by corticotroph pituitary adenomas (Cushing's Disease or CD) . The remaining ACTH-dependent cases mostly involve non-pituitary malignancies (Ectopic ACTH) which often are tumors of neuroendocrine origin such as small cell lung carcinoma or bronchial carcinoid [3, 4]. Here, we describe a case of Cushing's syndrome which initially appeared to be caused by ectopic ACTH secretion from metastatic small cell carcinoma. However, immunohistochemistry of the tumor cells was negative for ACTH expression, while corticotrophin releasing hormone (CRH) was strongly expressed, suggesting that the elevated ACTH levels were a result of pituitary secretion in response to CRH.
A 56 year old type 2 diabetic patient presented to the emergency room with shortness of breath. Review of systems revealed back pain for two weeks, without history of injury, and progressive generalized weakness and fatigue for many months. She also described constant right upper quadrant abdominal pain. On examination, there was hyperpigmentation of her face and neck in sun exposed areas, thin skin with violacious striae on her lower abdomen, and multiple ecchymoses over the extremities, abdomen and at venipuncture sites. There was prominent fat accumulation in the supraclavicular and dorsocervical regions. There also was objective evidence of proximal muscle weakness which, along with back pain, had caused her to be bed-ridden for two weeks. Her medications included an oral sulfonylurea for diabetes but no exogenous sources of corticosteroids. Laboratory results revealed hypokalemic alkalosis (K+ 2.1 mEq/l and HCO3 42 mEq/l). She was hyperglycemic (random glucose 339 mg/dl). An MRI of the spine showed multiple endplate compression fractures of the thoracic and lumbar vertebrae.
AT PRESENTATION (Normal Range)
Serum Potassium (3.8-5.2 mEq/l)
Serum HCO3 (21-32 mEq/l)
Plasma Glucose (mg/dl)
Morning Serum Cortisol (06:15) (4.0-32 μg/dl)
ENDOCRINE WORK-UP (Normal Range)
1 mg Overnight Dexamethasone Supression Test (Normal cortisol < 1.8 μg/dl)
48 hour High Dose Dexamethasone Supression Test (Normal cortisol < 1.8 μg/dl)
24 hour Urine Free Cortisol (0 to 50 μg)
Plasma ACTH (10-46 pg/ml)
Plasma CRHa (0-10 pg/ml)
Plasma Chromogranin A (0-5.0 nmol/l)
Serum Carcinoembryonic antigen (0-5.0 ng/ml)
Serum Calcitonin (0-5 pg/ml)
Serum Serotonin (0-420 ng/ml)
Plasma Metanephrine (0-62 pg/ml) and
Normetanephrine (0-145 pg/ml)
Serum Gastrin (13.0-115.0 pg/ml)
24 hr Urinary 5-HIAA (0-8.0 mg)
Because no primary lesion was found on imaging, a number of follow-up laboratory tests were performed. Chromogranin A and Carcinoembryonic antigen (CEA) were elevated consistent with a malignancy with neuroendocrine characteristics (Table 1). Laboratory tests for known causes of ectopic ACTH-namely, carcinoid (serotonin, 24 hour urine 5-hydroxy-indoleacteic acid), pheochromocytoma (plasma free metanephrines and normetanephrines), and medullary thyroid carcinoma (calcitonin)- were in the normal range (Table 1). Gastrin was over 2-fold higher than the upper limit of normal.
With the exception of the liver metastases and enlarged lymph nodes, there were no discrete lung nodules or neck, abdomen or pelvis lesions seen on CT. Scintigraphy with [111-In]pentreotide showed no tracer uptake at 4 hours. Specimens from bronchoalveolar lavage did not show any histologic findings of small cell lung carcinoma.
CRH Positive and ACTH negative Tumors causing Cushing's Syndrome
We believe our patient had a CRH secreting tumor due to strongly positive CRH staining, negative ACTH staining, and detectable plasma CRH. A simple explanation for the lack of ACTH immunostaining is that it is not expressed in the tumor cells. The polyclonal antibody used for our ACTH immunostaining also reacts with the parent propeptide, pro-opiomelanocortin, so that aberrant prohormone processing of POMC to ACTH is not an explanation. We have not examined whether POMC transcripts were present in the biopsy sample, but there is precedence that POMC RNA can be present without detectable pro-peptide or ACTH in the tissue [7, 18]. In these cases, it is not clear whether the POMC transcripts are not properly translated, or the ACTH is secreted too soon after production to be stored . In our patient, we only biopsied the metastatic lesions in the liver, so that we also cannot rule out that other non-hepatic metastatic lesions were able to produce ACTH.
An interesting aspect of this case is the lack of significant cortisol suppression by the high dose dexamethasone suppression test (HDDST; 2 mg dexamethasone every 6 hours for 48 hours), with baseline cortisol at 122.2 μg/dl before the test and 109 μg/dl after 48 hours. With isolated ectopic CRH, it is expected that CS develops through the stimulation of pituitary ACTH secretion with resultant adrenal cortisol production. Because of this, ACTH and cortisol levels potentially could suppress with HDDST, similar to a pituitary adenoma. Young and colleagues  reported this false positive suppression in a case of ectopic CRH-ACTH production, which also behaved like Cushing's disease by CRH stimulation testing and inferior petrosal sinus sampling (IPSS). However, in the case presented here as well as that of seven other ectopic CRH cases, the lack of suppression of ACTH and cortisol are consistent ectopic ACTH production, avoiding the superfluous performance of other, sometimes invasive, pituitary-centered procedures (e.g. IPSS) . Similarly, a single dose of 8 mg dexamethasone (overnight) has not suppressed cortisol in cases of isolated ectopic CRH [12, 17]. These findings confirm that the positive drive by CRH can overwhelm the negative feedback by elevated corticosteroid. The systemic CRH levels in the case reported here were at the upper end of normal. Most other published cases of ectopic CRH reports do not have the CRH levels available for comparison.
We present a rare case of isolated ectopic CRH production from metastatic small cell carcinoma of unknown primary. From the literature, the tumors most commonly associated with ectopic CRH production are medullary thyroid carcinoma, pheochromocytoma, and prostate cancer. With ectopic CRH syndrome, it is assumed that the pituitary is the source of ACTH with secretion driven by CRH overproduction. However, these tumors have behavior distinct from pituitary corticotroph adenomas, and the majority appears to lack suppression with high dose dexamethasone. Although the clinical presentation may be similar to ectopic ACTH syndrome, it is important to have ectopic CRH syndrome in the differential diagnosis for Cushing's syndrome.
The patient was deceased and attempts to contact the next of kin were not successful. Because of this, the case content was submitted to the Institutional Review Board and was determined to be exempt from IRB review.
Department of Medicine, Division of Diabetes, Endocrinology, and Metabolism and Department of Pathology, One Baylor Plaza, Mail Stop 285, Baylor College of Medicine, Houston, TX, 77030.
- Pivonello R, De Martino MC, De Leo M, Lombardi G, Colao A: Cushing's Syndrome. Endocrinol Metab Clin North Am. 2008, 37: 135-49. 10.1016/j.ecl.2007.10.010. ixView ArticlePubMedGoogle Scholar
- Lindholm J, Juul S, Jorgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U: Incidence and late prognosis of cushing's syndrome: a population-based study. J Clin Endocrinol Metab. 2001, 86: 117-123. 10.1210/jc.86.1.117.PubMedGoogle Scholar
- Vassiliadi D, Tsagarakis S: Unusual causes of Cushing's syndrome. Arq Bras Endocrinol Metabol. 2007, 51: 1245-1252.View ArticlePubMedGoogle Scholar
- Boscaro M, Arnaldi G: Approach to the patient with possible Cushing's syndrome. J Clin Endocrinol Metab. 2009, 94: 3121-3131. 10.1210/jc.2009-0612.View ArticlePubMedGoogle Scholar
- Ilias I, Torpy DJ, Pacak K, Mullen N, Wesley RA, Nieman LK: Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health. J Clin Endocrinol Metab. 2005, 90: 4955-4962. 10.1210/jc.2004-2527.View ArticlePubMedGoogle Scholar
- Isidori AM, Kaltsas GA, Pozza C, Frajese V, Newell-Price J, Reznek RH: The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up. J Clin Endocrinol Metab. 2006, 91: 371-377. 10.1210/jc.2005-1542.View ArticlePubMedGoogle Scholar
- Kristiansen MT, Rasmussen LM, Olsen N, Asa SL, Jorgensen JO: Ectopic ACTH syndrome: discrepancy between somatostatin receptor status in vivo and ex vivo, and between immunostaining and gene transcription for POMC and CRH. Horm Res. 2002, 57: 200-204. 10.1159/000058383.View ArticlePubMedGoogle Scholar
- Oates SK, Roth SI, Molitch ME: Corticotropin-releasing hormone-producing medullary thyroid carcinoma causing Cushing's syndrome: Clinical and pathological findings. Endocrine Pathology. 2000, 11: 277-285. 10.1385/EP:11:3:277.View ArticleGoogle Scholar
- Wajchenberg BL, Mendonca B, Liberman B, Adelaide M, Pereira A, Kirschner MA: Ectopic ACTH syndrome. J Steroid Biochem Mol Biol. 1995, 53: 139-151. 10.1016/0960-0760(95)00044-Z.View ArticlePubMedGoogle Scholar
- Eng PH, Tan LH, Wong KS, Cheng CW, Fok AC, Khoo DH: Cushing's syndrome in a patient with a corticotropin-releasing hormone-producing pheochromocytoma. Endocr Pract. 1999, 5: 84-87.View ArticlePubMedGoogle Scholar
- Ruggeri RM, Ferrau F, Campenni A, Simone A, Barresi V, Giuffre G: Immunohistochemical localization and functional characterization of somatostatin receptor subtypes in a corticotropin releasing hormone- secreting adrenal phaeochromocytoma: review of the literature and report of a case. Eur J Histochem. 2009, 53: 1-6.View ArticlePubMedGoogle Scholar
- Chrisoulidou A, Pazaitou-Panayiotou K, Georgiou E, Boudina M, Kontogeorgos G, Iakovou I: Ectopic Cushing's syndrome due to CRH secreting liver metastasis in a patient with medullary thyroid carcinoma. Hormones (Athens). 2008, 7: 259-262.Google Scholar
- Bayraktar F, Kebapcilar L, Kocdor MA, Asa SL, Yesil S, Canda S: Cushing's syndrome due to ectopic CRH secretion by adrenal pheochromocytoma accompanied by renal infarction. Exp Clin Endocrinol Diabetes. 2006, 114: 444-447. 10.1055/s-2006-924154.View ArticlePubMedGoogle Scholar
- Saeger W, Reincke M, Scholz GH, Ludecke DK: Ectopic ACTH- or CRH-secreting tumors in Cushing's syndrome. Zentralbl Pathol. 1993, 139: 157-163.PubMedGoogle Scholar
- Parenti G, Nassi R, Silvestri S, Bianchi S, Valeri A, Manca G: Multi-step approach in a complex case of Cushing's syndrome and medullary thyroid carcinoma. J Endocrinol Invest. 2006, 29: 177-181.View ArticlePubMedGoogle Scholar
- Jessop DS, Cunnah D, Millar JG, Neville E, Coates P, Doniach I: A phaeochromocytoma presenting with Cushing's syndrome associated with increased concentrations of circulating corticotrophin-releasing factor. J Endocrinol. 1987, 113: 133-138. 10.1677/joe.0.1130133.View ArticlePubMedGoogle Scholar
- Auchus RJ, Mastorakos G, Friedman TC, Chrousos GP: Corticotropin-releasing hormone production by a small cell carcinoma in a patient with ACTH-dependent Cushing's syndrome. J Endocrinol Invest. 1994, 17: 447-452.View ArticlePubMedGoogle Scholar
- Smallridge RC, Bourne K, Pearson BW, Van Heerden JA, Carpenter PC, Young WF: Cushing's syndrome due to medullary thyroid carcinoma: diagnosis by proopiomelanocortin messenger ribonucleic acid in situ hybridization. J Clin Endocrinol Metab. 2003, 88: 4565-4568. 10.1210/jc.2002-021796.View ArticlePubMedGoogle Scholar
- Young J, Deneux C, Grino M, Oliver C, Chanson P, Schaison G: Pitfall of petrosal sinus sampling in a Cushing's syndrome secondary to ectopic adrenocorticotropin-corticotropin releasing hormone (ACTH-CRH) secretion. J Clin Endocrinol Metab. 1998, 83: 305-308. 10.1210/jc.83.2.305.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.